A trial looking at camizestrant for early breast cancer (CAMBRIA-1)

This trial is looking at a new drug called camizestrant for early breast cancer that has a medium to high risk of coming back. It is comparing camizestrant with standard hormone treatment.

You pronounce camizestrant as cami-zess-trant.

This trial is for people who have had at least 2 years of hormone treatment after surgery. And whose breast cancer has:

• many receptors for the hormone oestrogen (ER positive cancer) and

• only a small number or no receptors for HER2. This is HER2 negative breast cancer.